- ICH GCP
- EU-Register für klinische Studien
Neueste Versuche
EudraCT Number: 2010-020047-12 | Sponsor Protocol Number: P090202 | Start Date: | |||||||||||
Sponsor Name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Etude de l'effet d'un traitement préventif par Nebivolol sur l'apparition et la progression de la dysfonction cardiaque chez les enfants atteints de dystrophie de Duchenne | |||||||||||||
Medical condition: Enfants atteints de dystrophie de Duchenne | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002936-97 | Sponsor Protocol Number: LTFU-ABO-101 | Start Date: | |||||||||||
Sponsor Name: Abeona Therapeutics Europe SL. | |||||||||||||
Full Title: A Long-term Follow-up Study of Patients with MPS IIIB from Gene Therapy Clinical Trials Involving the Administration of ABO-101 (rAAV9.CMV.hNAGLU) | |||||||||||||
Medical condition: MPS IIIB is a devastating lysosomal storage disease, caused by a N-α-acetylglucosaminidase (NAGLU) gene defect. Infants with MPS IIIB appear normal at birth, but the disease is relentlessly progres... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003801-15 | Sponsor Protocol Number: 12011.202 | Start Date: | |||||||||||
Sponsor Name: PARIPharma GmbH | |||||||||||||
Full Title: A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A ... | |||||||||||||
Medical condition: Bronchiolitis Obliterans Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023502-12 | Sponsor Protocol Number: UCL 08/0350 | Start Date: | ||||||||||||||||
Sponsor Name: University College London | ||||||||||||||||||
Full Title: A Proof of Principle, Double-Blind, Randomised Placebo-Controlled,Multi-centre Trial of pravaStatin to Ameliorate Early Onset Pre-eclampsia | ||||||||||||||||||
Medical condition: Pre-eclampsia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000928-17 | Sponsor Protocol Number: A/201/05 | Start Date: | |||||||||||
Sponsor Name: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Hyperthermic intra-arterial chemotherapy with oxaliplatin in total hepatic vascular exclusion. A Phase II study | |||||||||||||
Medical condition: no resecable liver metastasis from colo-rectal and gastric cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004641-27 | Sponsor Protocol Number: UZLeuven | Start Date: | |||||||||||
Sponsor Name: UZLeuven | |||||||||||||
Full Title: BOTOX in the treatment of urinary incontinence due to neurogenic detrusor overactivity in patients 3 months - 17 years | |||||||||||||
Medical condition: Urinary incontinence due to neurogenic detrusor overactivity | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000227-24 | Sponsor Protocol Number: RG_13-320 | Start Date: | |||||||||||
Sponsor Name: University of Birmingham | |||||||||||||
Full Title: A Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the treatment of relapsed or refractory primary central nervous system lymphoma | |||||||||||||
Medical condition: Relapsed or refractory primary central neurvous system lymphoma. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002383-40 | Sponsor Protocol Number: ICC_APL_Study_02 | Start Date: | ||||||
Sponsor Name: AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica | ||||||||
Full Title: Treatment study for children and adolescents with Acute Promyelocytic Leukemia | ||||||||
Medical condition: acute promyelocytic leukemia (APL) in children and adolescents | ||||||||
|
||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: IT (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002954-25 | Sponsor Protocol Number: ASND0036 | Start Date: | |||||||||||
Sponsor Name: Ascendis Pharma Growth Disorders A/S | |||||||||||||
Full Title: ApproaCH: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in C... | |||||||||||||
Medical condition: Achondroplasia (ACH) in prepubertal children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005478-24 | Sponsor Protocol Number: DYNE251-DMD-201 | Start Date: | |||||||||||
Sponsor Name: Dyne Therapeutics, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participan... | |||||||||||||
Medical condition: Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: IE (Ongoing) BE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |